The Center provides a range of diagnostic and predictive tests in dermatopathology. More than 9 thousand histological skin biopsies are evaluated annually for neoplastic and inflammatory conditions.

Unresectable or metastatic melanoma is tested for BRAF mutations. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma and is a predictive biomarker for treatment with BRAF inhibitor.

Dermatopathology is supervised by pathologist Justinas Pamedys.